

4.0.03 DOC Cmte minutes

VTE Diseases Committee meeting

Date: 04/02/2019

Location: NICE – Manchester

Minutes: FINAL



Committee members present:	
Susan Bewley (SB) (Chair)	Present for all
Michelle Greene (MG)	Present for all
Carol Hooper (CH)	Present for all
Daniel Horner (DH)	Present for all
Nigel Langford (NL)	Present until part way through item 5
Terry McCormack (TM)	Present for all
Karen Sheares (KS)	Present until part way through item 5
Hazel Trender (HT)	Present for all
Astrid Ullrich-Boereboom (AU)	Present for all

In attendance:		
Thomas Jarratt (TJ)	NICE – Technical Analyst	Present for all
Rui Martins (RM)	NICE – Health Economist	Present for all
Justine Karpusheff (JK)	NICE – Guidelines Commissioning Manager	Present until part way through item 5
Marie Harrisingh (MH)	NICE – Technical Adviser	Present for all
Bernadette Li (BL)	NICE – Technical Adviser (HE)	Present for all
Gail Montrose (GM)	NICE – Project Manager	Present until part way through item 3
Joanna Perkins (JP)	NICE pathways editor	Present for items 1 and 2
Ian Mather (IM)	Resource Impact Lead	Present for all
Elizabeth Barrett (EB)	NICE – Information Specialist	Present until part way through item 4

Apologies:

4.0.03 DOC Cmte minutes

Frances Akor	Committee member
Julia Anderson	Committee member
Sam Hare	Committee member
Simon McPherson	Committee member

Observer:

N/A		
-----	--	--

1. Introductions and guideline committee working

The Chair welcomed the Committee members and attendees to the 7th committee meeting on the management of VTE. The Committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received from those listed above.

The minutes were reviewed from the previous committee meeting (number 6) that was held on Monday 17th December 2018. The minutes were agreed to be an accurate record.

The Chair asked everyone to verbally declare any interests. No new interests were declared. The DOI register was made available to the Chair and committee. The Chair reviewed and considered the DOI register.

KS declared the renewal of a previously declared DOI and the chair advised the existing decision of 'Declare and participate' was appropriate.

The Chair outlined the objectives of the meeting: in particular, to review the evidence for the use of risk tools to predict VTE recurrence and major bleeding and draft recommendations; and to address issues arising with the economic modelling of extended pharmacological treatment.

2. Nice Pathways

JP presented to the committee an overview of the live pathway site and discussed the plans to update the VTE NICE pathway. JP requested volunteers to participate in the VTE Pathway.

The Chair thanked JP for the presentation and committee members volunteered to help update the pathway.

3. RQ 6.1 What factors determine the optimum duration of pharmacological treatment for DVT or PE in people with VTE?

4.0.03 DOC Cmte minutes

TJ presented the clinical evidence examining risk tools to predict VTE recurrence and major bleeding. The committee discussed the quality of the evidence and the application of the tools in practice and drafted recommendations accordingly.

4. RQ 3.1: What is the clinical and cost effectiveness of different pharmacological treatments for people with a confirmed diagnosis of DVT?
RQ 3.2: What is the clinical and cost effectiveness of different pharmacological treatments for people with a confirmed diagnosis of PE?
RQ 1.3: What is the clinical and cost effectiveness of different pharmacological treatments for people with suspected DVT prior to confirmed diagnosis?
RQ 2.4: What is the clinical and cost effectiveness of different pharmacological treatments for people with suspected PE prior to confirmed diagnosis?

MH and BL led a discussion with the committee about extended pharmacological treatment options; the potential for switching treatment from initial to extended therapy and the implications for economic modelling. The committee also continued a discussion from the previous meeting about the existing patient information recommendations and information aids.

5. Next steps

The Chair confirmed the venue, date and time of the next meeting, as detailed below and thanked the Committee and others present for their contributions before closing the meeting.

Date of next meeting: Monday 25th and Tuesday 26th March 2019

Location of next meeting: NICE – Manchester